tasquinimod (ABR-215050) / Active Biotech, Ipsen  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tasquinimod (ABR-215050) / Active Biotech, Ipsen
NCT01048203: A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects

Completed
1
6
Europe
ABR-215050, tasquinimod
Active Biotech AB
Healthy
03/09
03/09
NCT01513733: The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

Completed
1
25
US
tasquinimod, tasquinimod 0.25 mg; 0.5 mg, tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
Andrew J. Armstrong, MD
Prostate Cancer
06/15
06/16
NCT02396368: A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer

Withdrawn
1
0
US
Tasquinimod, Radium 223
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)
07/17
07/17
NCT04405167: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Recruiting
1
34
US
Tasquinimod, IRd chemotherapy, Ixazomib, Lenalidomide, Dexamethasone
University of Pennsylvania, Active Biotech AB
Multiple Myeloma
07/25
07/26

Download Options